Click Here to return To Results

 

Nusinersen Versus Sham Control in Infantile-Onset Spinal Muscular Atrophy NEJM 377:1723-1732,1786, Finkel, R.S.,et al, 2017 See this aricle in Pubmed Article Abstract Among infants with spinal muscular atrophy, those who received nusinersen were more likely to be alive and have improvements in motor function than those in the control group. Early treatment may be necessary to maximize the benefit of the drug.

Related Tags

(click to filter results - removes previous filter) children mortality motor neuron disease motor system nusinersen progressive neurologic disorder spinal muscular atrophy treatment of neurologic disorder Werdnig-Hoffman disease

Click Here to return To Results